ZAVESCA DIN 02250519
Health Canada record
| Active ingredient(s) | MIGLUSTAT 100 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A16AX06 MIGLUSTAT |
| Original market date | 26-May-2004 |
| Current status date | 04-Feb-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MIGLUSTAT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02556812 | OPFOLDA | AMICUS THERAPEUTICS CANADA INC. | Capsule | MIGLUSTAT 65 MG | Marketed |
| 02456257 | SANDOZ MIGLUSTAT | SANDOZ CANADA INCORPORATED | Capsule | MIGLUSTAT 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 21563 | 2018-11-23 | New Drug Submission (NDS) | MERGER - BUYOUT |
| 292 | 2004-03-31 | New Drug Submission (NDS) |
International API supply for MIGLUSTAT
4 active FDA Drug Master Files.
Request a quote for ZAVESCA